Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Patent
1996-01-16
1999-11-02
Huff, Sheela
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
5303873, 5303877, 4241311, 4241333, 4241381, A61K 39395
Patent
active
059773162
ABSTRACT:
The present invention relates to monoclonal antibody 1A7. This is an anti-idiotype produced by immunizing with an antibody specific for ganglioside GD2, and identifying a hybridoma secreting antibody with immunogenic potential in a multi-step screening process. Also disclosed are polynucleotide and polypeptide derivatives based on 1A7, including single chain variable region molecules and fusion proteins, and various pharmaceutical compositions. When administered to an individual, the 1A7 antibody overcomes immune tolerance and induces an immune response against GD2, which comprises a combination of anti-GD2 antibody and GD2-specific T cells. The invention further provides methods for treating a disease associated with altered GD2 expression, particularly melanoma, neuroblastoma, glioma, soft tissue sarcoma, and small cell carcinoma. Patients who are in remission as a result of traditional modes of cancer therapy may be treated with a composition of this invention in hopes of reducing the risk of recurrence.
REFERENCES:
patent: 4675287 (1987-06-01), Reisfeld et al.
patent: 4693966 (1987-09-01), Houghton et al.
patent: 4722840 (1988-02-01), Valenzuela et al.
patent: 4849509 (1989-07-01), Thurin et al.
patent: 4904596 (1990-02-01), Hakomori
patent: 4918164 (1990-04-01), Hellstrom et al.
patent: 5009995 (1991-04-01), Albino et al.
patent: 5053224 (1991-10-01), Koprowski et al.
patent: 5057540 (1991-10-01), Kensil et al.
patent: 5091177 (1992-02-01), Hellstrom et al.
patent: 5102663 (1992-04-01), Livingston et al.
patent: 5134075 (1992-07-01), Hellstrom et al.
patent: 5141742 (1992-08-01), Brown et al.
patent: 5208146 (1993-05-01), Irie
patent: 5240833 (1993-08-01), Nudelman et al.
patent: 5242824 (1993-09-01), Hellstrom et al.
patent: 5270202 (1993-12-01), Raychaudhuri
patent: 5308614 (1994-05-01), Hakomori
patent: 5529922 (1996-06-01), Chapman et al.
patent: 5571900 (1996-11-01), Wiegand et al.
patent: 5612030 (1997-03-01), Chatterjee et al.
patent: 5653977 (1997-08-01), Saleh
Angeles et al., "Isoabzymes: Structurally and mechanistically similar catalytic antibodies from the same immunization" Biochemistry (1993) 32:12128-12135.
Bhattacharya-Chatterjee et al., "Anti-idiotype antibodies as potential therapeutic agents for human breast cancer" In Antigen and Antibody Molecular Engineering in Breast Cancer Diagnosis and Treatment, Conference on Breast Cancer Therapy Immunology, R.L. Ceriani (Ed.), Plenum Press, N.Y., pp. 139-148, 1994.
Bhattacharya-Chatterjee et al., "Idiotype vaccines against human T cell acute lymphoblastic leukemia. I. Generation and characterization of biologically active monoclonal anti-idiotypes" J. Immunol. (1987) 139:1354-1360.
Bhattacharya-Chatterjee et al., "Idiotype vaccines against human T-cell leukemia" J. Immunol. (1988) 141:1398-1403.
Bhattacharya-Chatterjee et al., "Idiotypic antibody immunotherapy of cancer" Cancer Immunol. Immunother. (1994) 38:75-82.
Bhattacharya-Chatterjee et al., "Murine monoclonal anti-idiotype antibody as a potential network antigen for human carcinoembryonic antigen" J. Immunol. (1990) 145:2758-2765.
Bhattacharya-Chatterjee et al., "Syngeneic monoclonal anti-idiotype antibodies against a monoclonal antibody to human melanoma associated antigen" J. Immunol. (1993) 150:142A (Abstract 805).
Bird et al., "Single-chain antigen-binding proteins" Science (1988) 242:423-426.
Blier et al., "A limited number of B cell lineages generates the heterogeneity of a secondary immune response" J. Immunol. (1987) 139:3996-4006.
Chakraborty et al., "Induction of human breast cancer-specific antibody responses in cynomolgus monkeys by a murine monoclonal anti-idiotype antibody" Cancer Res. (1995) 55:1525-1530.
Chapman et al., "Induction of IgG antibodies against G.sub.D3 ganglioside in rabbits by an anti-idiotypic monoclonal antibody" J. Clin. Invest. (1991) 88:186-192.
Charbonnier et al., "Structural convergence in the active sites of a family of catalytic antibodies" Science (1997) 275:1140-1142.
Chattopadhyay et al., "Murine monoclonal anti-idiotope antibody breaks unresponsiveness and induces a specific antibody response to human melanoma-associated proteoglycan antigen in cynomolgus monkeys" Proc. Natl. Acad. Sci. USA (1992) 89:2684-2688.
Cheresh et al., "Biosynthesis and expression of the disialoganglioside G.sub.D2, a relevant target antigen on small cell lung carcinoma for monoclonal antibody-mediated cytolysis" Cancer Res. (1996) 46:5112-5118.
Cheresh et al., "Disialoganglioside G.sub.D2 and G.sub.D3 are involved in the attachment of human melanoma and neuroblastoma cells to extracellular matrix proteins" J. Cell. Biol. (1986) 102:688-696.
Cheresh et al., "Disialoganglioside GD.sub.2 distributes preferentially into substrate-associated microprocesses on human melanoma cells during their attachment to fibronectin" J. Cell. Biol. (1986) 102:1887-1897.
Cheresh et al., "Localization of the gangliosides G.sub.D2 and G.sub.D3 in adhesion plaques and on the surface of human melanoma cells" Proc. Natl. Sci. USA (1984) 81:5767-5771.
Cheung et al., "Antibody response to murine anti-G.sub.D2 monoclonal antibodies: correlation with patient survival" Cancer Res. (1994) 54:2228-2233.
Cheung et al., "Disialoganglioside G.sub.D2 anti-idiotypic monoclonal antibodies" Int. J. Cancer (1993) 54:499-505.
Cheung et al., "Ganglioside G.sub.D2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma" J. Clin. Oncol. (1987)5(9):1430-1440.
Cochran et al., "In vitro mutagenesis of the promoter region for a vaccinia virus gene: evidence for tandem early and late regulatory signals" J. Virol. (1985) 54:30-37.
Conry et al., "A carcinoembryonic antigen polynucleotide vaccine has in vivo antitumor activity" Gene Therapy (1995) 2:59-65.
Foon et al., "Immune response to the carcinoembryonic antigen in patients treated with an anti-idiotype antibody vaccine" J. Clin. Invest. (1995) 96:334-342.
Foon et al., "Anti-idiotype antibodies: novel therapeutic approach to cancer therapy" Immunology Series (1994) 61:281-292.
Guo et al., "Mechanistically different catalytic antibodies obtained from immunization with a single transition-state analog" Proc. Natl. Acad. Sci. USA (1995) 92:1694-1698.
Hamilton et al., "Ganglioside expression on human malignant melanoma assessed by quantitative immune thin-layer chromatography" Int. J. Cancer (1993) 53:566-573.
Hamilton et al., "Ganglioside expression on sarcoma and small-cell lung carcinoma compared to tumors of neuroectodermal origin" Proc. Am. Assoc. Cancer Res. (1993) 34:491 (Abstract 2928).
Handgretinger et al., "A phase I study of neuroblastoma with the anti-ganglioside GD2 antibody 14G2a" Cancer Immunol. Immunother. (1992) 35:199-204.
Hastings et al., "Production and characterization of a murine/human chimeric anti-idiotype antibody that mimics ganglioside" Cancer Res. (1992) 52:1681-1686.
Hawkins et al., "A genetic approach to idiotypic vaccination" J. Immunother. (1993) 14:273-278.
Hawkins et al., "Plasmid vaccination against B-cell lymphoma" Cancer Gene Therapy (1994) 1(3):208.
Heidenheim et al., "CDw60, which identifies the acetylated form of G.sub.D3 gangliosides, is strongly expressed in human basal cell carcinoma" Brit. J. Dermatol. (1995) 133:392-397.
Helling et al., "Ganglioside conjugate vaccines" Mol. Chem. Neuropath. (1994) 21:299-309.
Hruby et al., "Fine structure analysis and nucleotide sequence of the vaccinia virus thymidine kinase gene" Proc. Natl. Acad. Sci. USA (1983) 80:3411-3415.
Imclone Systems Incorporated Annual Report, 1995.
Irie et al., "Regression of cutaneous metastatic melanoma by intralesional injection with human monoclonal antibody to ganglioside GD2" Proc. Natl. Acad. Sci. USA (1986) 83:8694-8698.
Kanda et al., "Both V.sub.H and V.sub.L regions contribute to the antigenicity of anti-idiotypic antibody that mimics melanoma associated ganglioside GM.sub.3 " Cell Biophys. (1994) 24/25:65-74.
Kaufman et al., "A recombinant vaccinia virus expressing human carcinoembryonic antigen (CEA)" Int. J. Cancer (1991) 48:900-906.
Leahy et al., "Sequences of 12 monoclo
Chatterjee Malaya
Chatterjee Sunil K.
Foon Kenneth A.
Huff Sheela
Reeves Julie E.
The Board of Trustees of the University of Kentucky
LandOfFree
Monoclonal antibody 1A7 and related polypeptides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Monoclonal antibody 1A7 and related polypeptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Monoclonal antibody 1A7 and related polypeptides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2136942